Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Zanubrutinib Regimens in B-cell Malignancies
2020-000547-31Phase 3Unknown
- Sponsor
- BeiGene
- Start
- Aug 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zanubrutinib in B-cell malignancy, mature B-cell lymphoma and cancer, sponsored by BeiGene. Primary endpoint: Safety (TEAEs and SAEs). Status: unknown.
02
Drugs
zanubrutinib
03
Conditions
B-cell malignancymature B-cell lymphomacancer
Beyond the preview
Go deeper on 2020-000547-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000547-31.